Literature DB >> 15270130

Binding of imipramine to phospholipid bilayers using radioligand binding assay.

Z Fisar1, K Fuksová, M Velenovská.   

Abstract

Binding of the tricyclic antidepressant imipramine (IMI) to neutral and negatively charged lipid membranes was investigated using a radioligand binding assay combined with centrifugation or filtration. Lipid bilayers were composed of brain phosphatidylcholine (PC) and phosphatidylserine (PS). IMI binding isotherms were measured up to IMI concentration of 0.5 mmol/l. Due to electrostatic attraction, binding between the positively charged IMI and the negatively charged surfaces of PS membranes was augmented compared to binding to neutral PC membranes. After correction for electrostatic effects by means of the Gouy-Chapman theory, the binding isotherms were described both by surface partition coefficients and by binding parameters (association constants and binding capacities). It was confirmed that binding of IMI to model membranes is strongly affected by negatively charged phospholipids and that the binding is heterogeneous; in fact, weak surface adsorption and incorporation of the drug into the hydrophobic core of lipid bilayer can be seen and characterized. These results support the hypothesis suggesting that the lipid part of biological membranes plays a role in the mechanism of antidepressant action.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15270130

Source DB:  PubMed          Journal:  Gen Physiol Biophys        ISSN: 0231-5882            Impact factor:   1.512


  2 in total

1.  Bilayer composition, temperature, speciation effects and the role of bilayer chain ordering on partitioning of dexamethasone and its 21-phosphate.

Authors:  Sweta Modi; Bradley D Anderson
Journal:  Pharm Res       Date:  2013-07-25       Impact factor: 4.200

2.  In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383.

Authors:  Ayşe Ufuk; Graham Somers; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2015-07-30       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.